

## **ORGANISATIONAL RESTRUCTURE TO ACCELERATE COMMERCIAL EXECUTION AND REDUCE COSTS**

**Genetic Signatures [ASX: GSS]** (“GSS” or “the Company”), announced a significant organisational restructure designed to reduce operating costs, improve efficiency, and sharpen the Company's focus on sales growth, customer support and the broadening of its diagnostic product offering. The proposed changes follow a thorough review of the Company's operating structure, aimed at aligning resources with strategic priorities.

The Company is currently in consultation with impacted employees, which is expected to result in redundancies as part of the consolidation of internal functions, and transitioning aspects of product development to contract research organisations. The proposed changes will allow the Company to allocate greater focus and investment toward revenue-generating and customer-facing activities, while maintaining focus on its innovative technologies. Key elements of the proposed restructuring are summarised below:

### **Estimated Cost Reduction of \$5M from FY2027**

Following a comprehensive strategic review, the proposed restructuring is expected to result in up to 30 positions becoming redundant across the Company. In addition, further operational efficiencies have been identified which, together with the proposed redundancies, are expected to result in estimated cost savings of \$5 million from FY2027. One-off redundancy costs will be approximately \$800K depending on the outcome of the consultations. The Company has started to implement cost cutting measures and considers this an important step to achieving a leaner, more sustainable cost base as the Company scales its commercial operations.

### **Transition to Outsourced Product Development**

The Company will transition elements of product development to specialist contract research organisations, while maintaining core intellectual property and technical capabilities inhouse. This model is intended to provide the Company with access to flexible, best-in-class product development whilst reducing fixed costs and improving speed to market. The proposed restructuring prioritises investment in sales growth and customer support, which includes new products. The Company believes that a stronger commercial and customer-facing organisation is essential to driving product adoption in priority geographies and market segments.

### **Broadened Product Offering**

The Company intends to increase its focus on expanding its product portfolio. This includes advancing new product initiatives and compiling and publishing clinical data for the existing product portfolio, with the goal of addressing a broader range of customer needs, clinical applications and targeting new markets.

Chief Executive Officer Maria Halasz said these changes form the initial part of a broader program to strengthen the Company's operational discipline and focus on growth. “My priority is to ensure the Company is structured to support both disciplined cost management and the successful development and commercialisation of our diagnostic products,” Ms Halasz said.

Chair of the Board, Caroline Waldron, said the restructure marks an important step in positioning the Company for sustainable growth. "Restructures of this nature are difficult, and I want to acknowledge all employees who have contributed to the Company, including those who may be affected. Any impacted employees will receive their full entitlements in accordance with Company policy and applicable law." Ms Waldron said.

The Company will provide further updates as required in accordance with its continuous disclosure obligations.

– END –

**Announcement authorised by Genetic Signatures' Board of Directors**

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us:

**Daniel Ireland**

**Investor Relations**

[Daniel.ireland@datair.com.au](mailto:Daniel.ireland@datair.com.au)

0428 607 884

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious agents, using patented 3base® technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.